Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two randomised, double-masked, phase 3 trials
- YOSEMITE and RHINE Investigators
- Houston Methodist
- Genentech, Inc
- Roche Products (Ireland)
- Retina Vitreous Associates of Florida
- University of South Florida
- Tel Aviv Sourasky Medical Center
- Liverpool University Hospitals NHS Foundation Trust
- Kagoshima University
- Organización Médica de Investigación
- Roche Products Limited UK
- Joslin Diabetes Center
- Palmetto Retina Center
- Université Paris Cité
- Institut Français de Myopie
Research output: Contribution to journal › Article › peer-review
421
Link opens in a new tab
Scopus
citations